Quick answer
Could a pill help with ulcerative colitis?
A phase 2b clinical trial led by Cedars-Sinai found that a once-daily oral pill called icotrokinra was more effective than placebo in adults with moderate-to-severe ulcerative colitis. The results, published in The New England Journal of Medicine, point to a new treatment option for this chronic digestive disease.
What is ulcerative colitis and why does a new oral option matter?
Ulcerative colitis is a chronic and debilitating condition that causes inflammation and ulcers in the lining of the large intestine. An estimated 3.1 million adults in the United States have been diagnosed with it, according to the Centers for Disease Control and Prevention. Symptoms can include:
- Frequent diarrhea with blood
- Abdominal pain
- Malnutrition
- Anemia
- Joint pain
Many advanced therapies for ulcerative colitis are given through injections or infusions, so a once-daily oral pill could make a meaningful difference in daily routines. Although research is still ongoing, the recent findings suggest that oral options may be workable.
How does icotrokinra work in the body?
Icotrokinra blocks the effects of IL-23, a protein in the immune system that contributes to harmful inflammation in the intestinal lining. Unlike many advanced therapies, this medication is taken as a pill. Earlier this year, the U.S. Food and Drug Administration (FDA) approved icotrokinra for the treatment of plaque psoriasis. Researchers explained that it is not unusual for a drug that works against one immune-related condition to also benefit people with another, because the IL-23 pathway can be relevant for both psoriasis and inflammatory bowel disease.
What did the ANTHEM-UC clinical trial show?
In the phase 2b ANTHEM-UC trial, conducted in 21 countries, participants were randomly assigned to receive icotrokinra or a placebo. Almost half of the study patients had received advanced therapies, such as biologic medications, while the rest were taking conventional anti-inflammatory drugs. Icotrokinra showed benefit in the study's primary evaluation at 12 weeks, and patients maintained remission during the 28 weeks of treatment. According to the authors, icotrokinra was effective even in difficult-to-treat patients who had not responded to previous drug treatments. The fact that the medication can be taken orally may help expand the options available to patients.
What does this mean for people living with ulcerative colitis?
The study suggests that a once-daily oral pill could expand treatment options for people with moderate-to-severe ulcerative colitis, particularly in the early stages of the disease. The researchers described a favorable safety profile and a precise mechanism of action, and they mentioned hoping to study icotrokinra for Crohn's disease as well. It is important to remember that these findings come from a clinical trial and are not individual medical advice. People who live with persistent digestive symptoms or related joint pain can talk with a health professional about suitable options. At SANAA Experience, approaches for managing chronic pain are explored, though each case requires personalized evaluation.
Frequently asked questions
Is icotrokinra already approved for ulcerative colitis?
No. Icotrokinra is approved by the FDA for plaque psoriasis, not for ulcerative colitis. The published study is a phase 2b trial, and further research is needed before it can be considered an approved option for this digestive disease.
Did the trial only include patients from the United States?
No. The ANTHEM-UC clinical trial was conducted in 21 countries and randomly assigned participants to receive icotrokinra or placebo. Almost half had received advanced therapies, such as biologic medications, which suggests the study included people with different treatment histories.
What effects were observed in the study?
The researchers observed that icotrokinra was significantly more effective than placebo in the primary evaluation at 12 weeks, and patients maintained remission during 28 weeks of treatment. The safety profile was described as favorable by the authors.
Could icotrokinra also help with Crohn's disease?
It is not known yet. The researchers mentioned they hope to study icotrokinra for Crohn's disease as well, but the published results so far relate only to ulcerative colitis.